Cocrystal Pharma Net Worth
Cocrystal Pharma Net Worth Breakdown | COCP |
Cocrystal Pharma Net Worth Analysis
Cocrystal Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cocrystal Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cocrystal Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cocrystal Pharma's net worth analysis. One common approach is to calculate Cocrystal Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cocrystal Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cocrystal Pharma's net worth. This approach calculates the present value of Cocrystal Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cocrystal Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cocrystal Pharma's net worth. This involves comparing Cocrystal Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cocrystal Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Cocrystal Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cocrystal Pharma's net worth research are outlined below:
| Cocrystal Pharma may become a speculative penny stock | |
| Cocrystal Pharma had very high historical volatility over the last 90 days | |
| Cocrystal Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (17.98 M) with loss before overhead, payroll, taxes, and interest of (8.79 M). | |
| Cocrystal Pharma currently holds about 51.03 M in cash with (14.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cocrystal Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 32.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Linscott Walt Addison of 1200000 shares of Cocrystal Pharma at 0.98 subject to Rule 16b-3 |
Cocrystal Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cocrystal Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cocrystal Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cocrystal Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cocrystal Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cocrystal Pharma backward and forwards among themselves. Cocrystal Pharma's institutional investor refers to the entity that pools money to purchase Cocrystal Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-09-30 | 2.7 K | Ubs Group Ag | 2024-09-30 | 910 | Northwestern Mutual Wealth Management Co | 2024-09-30 | 817 | Clean Yield Group Inc | 2024-09-30 | 418 | Jpmorgan Chase & Co | 2024-09-30 | 411 | Nvwm, Llc | 2024-09-30 | 84.0 | Royal Bank Of Canada | 2024-09-30 | 51.0 | Advisor Group Holdings, Inc. | 2024-09-30 | 17.0 | Activest Wealth Management | 2024-09-30 | 1.0 | Vanguard Group Inc | 2024-09-30 | 275.7 K | Renaissance Technologies Corp | 2024-09-30 | 130 K |
Follow Cocrystal Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.94 M.Market Cap |
|
Project Cocrystal Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.60) | |
| Return On Capital Employed | (0.66) | (0.70) | |
| Return On Assets | (0.58) | (0.60) | |
| Return On Equity | (0.68) | (0.65) |
When accessing Cocrystal Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cocrystal Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cocrystal Pharma's profitability and make more informed investment decisions.
Evaluate Cocrystal Pharma's management efficiency
Cocrystal Pharma has return on total asset (ROA) of (0.4606) % which means that it has lost $0.4606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6886) %, meaning that it created substantial loss on money invested by shareholders. Cocrystal Pharma's management efficiency ratios could be used to measure how well Cocrystal Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/11/2024, Return On Tangible Assets is likely to drop to -0.6. In addition to that, Return On Capital Employed is likely to drop to -0.7. As of 12/11/2024, Non Current Liabilities Other is likely to grow to about 366.4 K, while Total Current Liabilities is likely to drop slightly above 2.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.73 | 2.60 | |
| Tangible Book Value Per Share | 2.73 | 2.87 | |
| Enterprise Value Over EBITDA | 0.41 | 0.43 | |
| Price Book Value Ratio | 0.63 | 0.60 | |
| Enterprise Value Multiple | 0.41 | 0.43 | |
| Price Fair Value | 0.63 | 0.60 | |
| Enterprise Value | 88.6 M | 88.5 M |
Cocrystal Pharma showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 17.8912 | Revenue 510 K | Quarterly Revenue Growth 0.269 | Revenue Per Share 0.006 | Return On Equity (0.69) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cocrystal Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cocrystal Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cocrystal Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cocrystal Pharma time-series forecasting models is one of many Cocrystal Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cocrystal Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Cocrystal Pharma Earnings per Share Projection vs Actual
Cocrystal Pharma Corporate Executives
Elected by the shareholders, the Cocrystal Pharma's board of directors comprises two types of representatives: Cocrystal Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cocrystal. The board's role is to monitor Cocrystal Pharma's management team and ensure that shareholders' interests are well served. Cocrystal Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cocrystal Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sam Lee | Co-Founder and Pres | Profile | |
| Roger Kornberg | Independent CoFounder | Profile | |
| Prof Kornberg | Independent CoFounder | Profile |
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.